Episurf Medical AB (STU:16E) Piotroski F-Score: 3 (As of Jul. 24, 2026) — 25% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Episurf Medical AB Piotroski F-Score?

Episurf Medical AB STU:16E Piotroski F-Score is 3 as of Jul. 24, 2026, which is 25% below its 10-year median of 4.00. The stock has 7 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Episurf Medical AB ranks worse than 76.96% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Episurf Medical AB has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Episurf Medical AB's Piotroski F-Score or its related term are showing as below:

STU:16E' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 6
Current: 3

During the past 13 years, the highest Piotroski F-Score of Episurf Medical AB was 6. The lowest was 2. And the median was 4.

Episurf Medical AB  (STU:16E) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Episurf Medical AB Piotroski F-Score Related Terms


Episurf Medical AB Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Episurf Medical AB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Episurf Medical AB Piotroski F-Score Chart

Episurf Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 3.00 4.00 4.00 2.00

Episurf Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 3.00 2.00 3.00

STU:16E vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Episurf Medical AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Episurf Medical AB Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Episurf Medical AB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Episurf Medical AB's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -1.607 + -0.945 + -1.241 + -2.497 = €-6.29 Mil.
Cash Flow from Operations was -1.326 + -1.273 + -1.075 + 1.068 = €-2.61 Mil.
Revenue was 0.263 + 0.291 + 0.322 + 0.279 = €1.16 Mil.
Gross Profit was 0.2 + 0.2 + 0.184 + -0.028 = €0.56 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(7.832 + 6.193 + 6.963 + 5.495 + 67.03) / 5 = €18.7026 Mil.
Total Assets at the begining of this year (Mar25) was €7.83 Mil.
Long-Term Debt & Capital Lease Obligation was €0.13 Mil.
Total Current Assets was €3.86 Mil.
Total Current Liabilities was €11.35 Mil.
Net Income was -1.896 + -1.401 + -1.574 + 0.137 = €-4.73 Mil.

Revenue was 0.283 + 0.299 + 0.296 + 0 = €0.88 Mil.
Gross Profit was 0.319 + 0.194 + 0.313 + -0.055 = €0.77 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(7.255 + 11.835 + 9.997 + 8.502 + 7.832) / 5 = €9.0842 Mil.
Total Assets at the begining of last year (Mar24) was €7.26 Mil.
Long-Term Debt & Capital Lease Obligation was €0.33 Mil.
Total Current Assets was €3.88 Mil.
Total Current Liabilities was €1.37 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Episurf Medical AB's current Net Income (TTM) was -6.29. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Episurf Medical AB's current Cash Flow from Operations (TTM) was -2.61. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-6.29/7.832
=-0.80311542

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-4.734/7.255
=-0.65251551

Episurf Medical AB's return on assets of this year was -0.80311542. Episurf Medical AB's return on assets of last year was -0.65251551. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Episurf Medical AB's current Net Income (TTM) was -6.29. Episurf Medical AB's current Cash Flow from Operations (TTM) was -2.61. ==> -2.61 > -6.29 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.13/18.7026
=0.00695091

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0.329/9.0842
=0.03621673

Episurf Medical AB's gearing of this year was 0.00695091. Episurf Medical AB's gearing of last year was 0.03621673. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=3.862/11.345
=0.34041428

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=3.88/1.369
=2.83418554

Episurf Medical AB's current ratio of this year was 0.34041428. Episurf Medical AB's current ratio of last year was 2.83418554. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Episurf Medical AB's number of shares in issue this year was 1963.497. Episurf Medical AB's number of shares in issue last year was 700.239. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.556/1.155
=0.48138528

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.771/0.878
=0.87813212

Episurf Medical AB's gross margin of this year was 0.48138528. Episurf Medical AB's gross margin of last year was 0.87813212. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1.155/7.832
=0.14747191

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0.878/7.255
=0.12101999

Episurf Medical AB's asset turnover of this year was 0.14747191. Episurf Medical AB's asset turnover of last year was 0.12101999. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Episurf Medical AB has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Episurf Medical AB (STU:16E) has a Piotroski F-Score of 3 as of Jul. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Episurf Medical AB and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Episurf Medical AB's Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Episurf Medical AB ranks #618 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 77%.
Is Episurf Medical AB's Piotroski F-Score too high?
Episurf Medical AB's current Piotroski F-Score of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Episurf Medical AB's value of 3 is 40% below this industry median. Based on the distribution chart, Episurf Medical AB ranks #618 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Episurf Medical AB's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Episurf Medical AB ranks #618 out of 803 companies for Piotroski F-Score. This places Episurf Medical AB in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Episurf Medical AB's value of 3 is 40% below this benchmark. Historically, Episurf Medical AB's own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Episurf Medical AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Episurf Medical AB's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Episurf Medical AB and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Episurf Medical AB's current Piotroski F-Score is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Episurf Medical AB stock overvalued right now?
Episurf Medical AB (STU:16E) has a current Piotroski F-Score of 3. The current Piotroski F-Score is 3, which is 25% below median its 10-year median of 4.00 and 40% below the Medical Devices & Instruments industry median of 5.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Episurf Medical AB (STU:16E), the current Piotroski F-Score is 3 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Episurf Medical AB Business Description

Other Exchanges EPIS B:Sweden0QUT:UK
Address Karlavagen 60, Stockholm, SWE, 114 49
Episurf Medical AB is a medical device company. The company develops, manufactures, and commercializes solutions for the repair of the local cartilage damage in human joints. Its first patient-specific product portfolio, the knee portfolio, consists of the existing products Episealer Condyle Solo and Episealer Trochlea Solo, Episealer Femoral Twin, Epiguide MOS, and Epioscopy. Episealer Patellofemoral System for the treatment of osteoarthritis limited to thepatellofemoral part of the knee joint. The company is forming a new strategic business segment through the acquisition of real estate assets.